Supplementary Figure S12 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
<p>Supplementary Figure S12 shows RNA-seq fold changes of differentially expressed genes shared between crizotinib vs vehicle and lorlatinib vs vehicle.</p>
Authors
- Jo Lynne Rokita (ORCID: https://orcid.org/0000-0003-2171-3627)
- John M. Maris (ORCID: https://orcid.org/0000-0002-8088-7929)
- Mark Gerelus (ORCID: https://orcid.org/0000-0001-8986-4523)
- Esther R. Berko (ORCID: https://orcid.org/0000-0001-7181-1378)
- Smita Matkar (ORCID: https://orcid.org/0000-0002-5697-2576)
- Yaël P. Mossé (ORCID: https://orcid.org/0000-0002-3463-0399)
- Gabriela M. Witek (ORCID: https://orcid.org/0000-0003-2635-773X)
- Timothy Joseph Stuhlmiller (ORCID: https://orcid.org/0009-0005-0946-2257)
- Gary L. Johnson (ORCID: https://orcid.org/0000-0003-2867-0551)
- Kateryna Krytska
- Joshua R. Kalna
- Alvin Farrel (ORCID: https://orcid.org/0000-0003-1087-9840)
- Colleen E. Casey (ORCID: https://orcid.org/0009-0004-9259-1035)
- Denis O. Okumu (ORCID: https://orcid.org/0000-0002-4791-0453)
- Michael P. East (ORCID: https://orcid.org/0000-0002-1994-6117)
- Steven Pastor (ORCID: https://orcid.org/0000-0002-4204-1383)
- Khushbu Patel (ORCID: https://orcid.org/0000-0002-3269-7442)
- Anne Kennedy (ORCID: https://orcid.org/0000-0003-2701-2637)
Publication Details
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1158/1535-7163.30028822
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00